Prognostic Value of Stress Cardiac Magnetic Resonance in Patients With Known Coronary Artery Disease

Panagiotis Antiochos, Yin Ge, Bobak Heydari, Kevin Steel, Scott Bingham, Shuaib M Abdullah, J Ronald Mikolich, Andrew E Arai, W Patricia Bandettini, Amit R Patel, Afshin Farzaneh-Far, John F Heitner, Chetan Shenoy, Steve W Leung, Jorge A Gonzalez, Dipan J Shah, Subha V Raman, Victor A Ferrari, Jeanette Schulz-Menger, Matthias Stuber, Orlando P Simonetti, Raymond Y Kwong, Panagiotis Antiochos, Yin Ge, Bobak Heydari, Kevin Steel, Scott Bingham, Shuaib M Abdullah, J Ronald Mikolich, Andrew E Arai, W Patricia Bandettini, Amit R Patel, Afshin Farzaneh-Far, John F Heitner, Chetan Shenoy, Steve W Leung, Jorge A Gonzalez, Dipan J Shah, Subha V Raman, Victor A Ferrari, Jeanette Schulz-Menger, Matthias Stuber, Orlando P Simonetti, Raymond Y Kwong

Abstract

Objectives: This study sought to determine whether stress cardiac magnetic resonance (CMR) provides clinically relevant risk reclassification in patients with known coronary artery disease (CAD) in a multicenter setting in the United States.

Background: Despite improvements in medical therapy and coronary revascularization, patients with previous CAD account for a disproportionately large portion of CV events and pose a challenge for noninvasive stress testing.

Methods: From the Stress Perfusion Imaging in the United States (SPINS) registry, we identified consecutive patients with documented CAD who were referred to stress CMR for evaluation of myocardial ischemia. The primary outcome was nonfatal myocardial infarction (MI) or cardiovascular (CV) death. Major adverse CV events (MACE) included MI/CV death, hospitalization for heart failure or unstable angina, and late unplanned coronary artery bypass graft. The prognostic association and net reclassification improvement by ischemia for MI/CV death were determined.

Results: Out of 755 patients (age 64 ± 11 years, 64% male), we observed 97 MI/CV deaths and 210 MACE over a median follow-up of 5.3 years. Presence of ischemia demonstrated a significant association with MI/CV death (HR: 2.30; 95% CI: 1.54-3.44; P < 0.001) and MACE (HR: 2.24 ([95% CI: 1.69-2.95; P < 0.001). In a multivariate model adjusted for CV risk factors, ischemia maintained strong association with MI/CV death (HR: 1.84; 95% CI: 1.17-2.88; P = 0.008) and MACE (HR: 1.77; 95% CI: 1.31-2.40; P < 0.001) and reclassified 95% of patients at intermediate pretest risk (62% to low risk, 33% to high risk) with corresponding changes in the observed event rates of 1.4% and 5.3% per year for low and high post-test risk, respectively.

Conclusions: In a multicenter cohort of patients with known CAD, CMR-assessed ischemia was strongly associated with MI/CV death and reclassified patient risk beyond CV risk factors, especially in those considered to be at intermediate risk. Absence of ischemia was associated with a <2% annual rate of MI/CV death. (Stress CMR Perfusion Imaging in the United States [SPINS] Study; NCT03192891).

Keywords: coronary artery disease; ischemia; risk reclassification; stress cardiac magnetic resonance.

Conflict of interest statement

Funding Support and Author Disclosures The SPINS study of the Society for Cardiovascular Magnetic Resonance (SCMR) registry was funded by the SCMR with a research grant jointly sponsored by Siemens Healthineers (Erlangen, Germany) and Bayer (Leverkusen, Germany). These sponsors provided financial support for the study but did not play a role in study design, data collection, analysis, interpretation, or manuscript drafting. Dr Antiochos has received research funding from the Swiss National Science Foundation (grant P2LAP3_184037), the Novartis Foundation for Medical-Biological Research, the Bangerter-Rhyner Foundation, and the SICPA Foundation. Dr Bandettini is the principal investigator of one of the Bayer-sponsored GadaCAD2 (Gadavist-Enhanced Cardiac Magnetic Resonance Imaging to Detect Coronary Artery Disease) sites. Dr Patel has received a research grant from and served on the Speakers Bureau of Astellas. Dr Raman has received institutional research support from Siemens. Dr Schulz-Menger has research agreements with Siemens and serves on the Advisory Board of Bayer. Dr Shenoy has received support from a National Institutes of Health grant (K23HL132011). Dr Stuber has received nonmonetary research support form Siemens Healthineers. Dr Simonetti receives institutional research support from Siemens. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Copyright © 2022 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Source: PubMed

3
Subskrybuj